Abiopharma

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

Ovid Therapeutics Inc. - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference